Market
ENGLISH DEUTSCH
After approval REDECTANE® could be used before every planned surgical removal of a renal tumour in order to determine whether it is a clear cell renal cell carcinoma. In the Company’s view, using REDECTANE® and PET/CT for diagnosis could greatly enhance the precision of renal cancer diagnosis and thus bring about crucial changes in therapy monitoring. The therapy planning of renal cancer patients could improve fundamentally and unneccessary surgery could be avoided. Furthermore, REDECTANE® may also prove suitable for diagnosing other kinds of tumours. Wilex is not aware of a similar imaging procedure existing today.
The peak sales potential for the diagnosis of clear cell RCC is approximately USD 100 million.
In June 2008 WILEX signed an agreement with Ion Beam Application S.A., Brussels, Belgium for REDECTANE® for the worldwide marketing, distribution and sale as well as for the manufacturing.
At the same time, WILEX is also preparing marketing activities in the United States in cooperation with its partner IBA. This includes not only conducting in-depth market research but also expanding and maintaining our contacts to oncologists and urologists (key opinion leaders).
